Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Chemotherapy of cervix cancer with doxorubicin and cisplatin

A phase I pilot study of the Gynecologic Oncology Group

Omura, George A., M.D.; Hubbard, Judy, R.N.; Hatch, Kenneth, M.D.

American Journal of Clinical Oncology: October 1985 - Volume 8 - Issue 5 - p 347–349
Article: PDF Only

TWELVE WOMEN WITH PREVIOUSLY IRRADIATED ADVANCED PELVIC CANCER were treated with doxorubicin and cisplatin to determine a maximum tolerable dose. Response was not an objective of this phase I study, but one partial response was seen in four cases of cervix cancer with measurable lesions. Hematologic toxicity was frequent and severe at the starting doses (doxorubicin 30 mg/M2 and cisplatin 100 mg/ M2 every 3 weeks), but was acceptable when cisplatin was used at 75 mg/M2. Further evaluation of this combination in squamous carcinoma of the cervix is not recommended.

From the University of Alabama at Birmingham.

© Lippincott-Raven Publishers.